UNICHEMLAB
Unichem Laboratories Limited (UNICHEMLAB) Stock Analysis
Unichem Laboratories Limited is an Indian pharmaceutical company manufacturing APIs and formulations for domestic and export markets. It has a long heritage in generics spanning cardiovascular, gastro, and other therapies. The company operates WHO-GMP plants and sells through Unichem and licensing partners. It is listed on the NSE and BSE.
Healthcare › Drug Manufacturers - Specialty & Generic
₹531.10
-0.74% 1W | +12.30% 52W
Market Cap
3.7k CR
P/E Ratio
12.3
52W High
₹687.2
52W Low
₹278.2
Div. Yield
0%
Beta
-0
50 DMA
₹536.2
200 DMA
₹431
Profit Margin
13.2%
Inst. Own.
10.2%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 423 | 416 | 466 | 432 | 483 | 507 | 533 | 587 | 527 | 579 | 521 | 575 | 633 |
| Expenses | 395 | 407 | 435 | 406 | 443 | 452 | 448 | 503 | 504 | 513 | 476 | 527 | 563 |
| Operating Profit | 28 | 9 | 31 | 25 | 40 | 55 | 86 | 84 | 22 | 66 | 45 | 48 | 70 |
| OPM % | 7% | 2.1% | 7% | 6% | 8% | 11% | 16% | 14% | 4.3% | 11% | 9% | 8% | 11% |
| Other Income | 9 | 6 | 79 | -119 | 4 | 9 | 14 | 9 | 7 | -37 | 287 | 11 | 16 |
| Interest | 6 | 7 | 6 | 5 | 4 | 5 | 7 | 5 | 7 | 8 | 7 | 9 | 7 |
| Depreciation | 29 | 29 | 32 | 27 | 32 | 32 | 31 | 30 | 32 | 31 | 31 | 31 | 30 |
| Profit before tax | 2 | -22 | 73 | -126 | 8 | 27 | 62 | 58 | -9 | -11 | 293 | 19 | 49 |
| Tax % | 132% | 12% | -0% | 3% | 74% | 9% | 6% | 8% | 16% | 10% | 10% | 42% | 15% |
| Net Profit | -1 | -24 | 73 | -129 | 2 | 25 | 58 | 53 | -10 | -12 | 264 | 11 | 41 |
| EPS in Rs | -0.10 | -3.48 | 10.40 | -18.37 | 0.29 | 3.50 | 8.22 | 7.52 | -1.49 | -1.69 | 37.54 | 1.55 | 5.89 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,202 | 1,333 | 698 | 815 | 1,180 | 1,104 | 1,235 | 1,270 | 1,343 | 1,785 | 2,111 | 2,202 | 2,308 |
| Expenses | 1,100 | 1,169 | 738 | 942 | 1,254 | 1,153 | 1,144 | 1,198 | 1,389 | 1,698 | 1,846 | 2,013 | 2,079 |
| Operating Profit | 101 | 164 | -41 | -128 | -74 | -49 | 91 | 72 | -46 | 87 | 265 | 189 | 229 |
| OPM % | 8% | 12% | -6% | -16% | -6% | -4.5% | 7% | 6% | -3.4% | 4.9% | 13% | 9% | 10% |
| Other Income | 20 | 15 | 184 | 2,735 | 91 | 91 | 50 | 47 | -0 | -26 | 35 | 260 | 277 |
| Interest | 3 | 3 | 3 | 8 | 8 | 8 | 5 | 6 | 17 | 23 | 21 | 32 | 32 |
| Depreciation | 41 | 39 | 44 | 51 | 67 | 82 | 84 | 91 | 113 | 123 | 125 | 125 | 123 |
| Profit before tax | 77 | 137 | 97 | 2,548 | -58 | -48 | 51 | 22 | -176 | -85 | 155 | 292 | 350 |
| Tax % | 3% | 21% | -12% | 0% | -59% | 25% | 33% | -50% | 15% | 10% | 11% | 14% | |
| Net Profit | 75 | 108 | 109 | 2,545 | -24 | -60 | 34 | 33 | -202 | -94 | 138 | 253 | 305 |
| EPS in Rs | 8.31 | 11.90 | 11.96 | 361.82 | -3.38 | -8.55 | 4.87 | 4.70 | -28.72 | -13.32 | 19.53 | 35.91 | 43.29 |
| Dividend Payout % | 24% | 17% | 25% | 1% | -118% | -47% | 82% | 85% | -14% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 18.0% | 12.0% | 5.0% |
| Profit CAGR | 35.0% | 25.0% | -3.0% |
Shareholding Pattern
Promoters70.22%
FIIs0.98%
DIIs10.92%
Public17.88%
Promoters70.22%
FIIs0.99%
DIIs10.74%
Public18.04%
Promoters70.22%
FIIs0.99%
DIIs10.73%
Public18.05%
Promoters70.22%
FIIs1.00%
DIIs10.63%
Public18.14%
Promoters70.22%
FIIs0.90%
DIIs10.46%
Public18.41%
Promoters50.94%
FIIs1.70%
DIIs8.15%
Public39.21%
Promoters70.22%
FIIs0.90%
DIIs11.26%
Public17.63%
Promoters70.22%
FIIs0.98%
DIIs11.32%
Public17.47%
Promoters70.22%
FIIs1.00%
DIIs10.63%
Public18.14%
Promoters70.22%
FIIs0.90%
DIIs10.46%
Public18.41%
UNICHEMLAB
Holdings Analysis
Key strengths & risk signals
64
Overall
57
Fundamental
71
Technical
Risks (3)
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
RECOVERY MODE! Current price (531.1) above 200-day but below 50-day.
NEGATIVE MOMENTUM! Price declined across timeframes - down 0.7% (1 week), 2.1% (1 month), 16.9% (3 months).
Strengths (4)
Cannot calculate PEG - insufficient growth data.
BULLISH TREND! 50-day average (536.2) is above 200-day average (431.0) - positive signal.
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 441,870 vs down days: 120,164. Ratio: 3.68x
UPPER HALF! Trading at 61.8% of 52W range - positive territory.
Fundamental & Technical Analysis
64Overall
57Fundamental
71Technical
Fundamental Breakdown
Growth Quality
15/30
Revenue CAGR: 18.4% (VERY GOOD, 13/15). Profit CAGR: 0% (DECLINING, 2/15).
Profit Margin
5/10
DECENT EFFICIENCY! 13.2% profit margin - acceptable profitability.
PEG Valuation
10/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
10/20
SIGNIFICANT PUBLIC HOLDING! 37.8% public ownership - moderate retail influence.
Stability Index
4/10
CAREFUL! Company does not have stable profit track. 2 loss-making quarters detected.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (536.2) is above 200-day average (431.0) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (531.1) above 200-day but below 50-day.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
6/10
POSITIVE YEAR! Stock gained 12.3% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 441,870 vs down days: 120,164. Ratio: 3.68x
RSI
3/5
NEUTRAL! RSI at 46.7 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 61.8% of 52W range - positive territory.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 0.7% (1 week), 2.1% (1 month), 16.9% (3 months).
Beta
3/5
MARKET ALIGNED! Beta of 1.00 - moves with the market.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UNICHEMLAB | ₹531.10 | 12.3 | 13.2% | 18.4% | – | +12.3% | 64 | BREAKDOWN | -495.2% | +280.7% | +20.1% | +10.0% |
| AARTIDRUGS | ₹413.30 | 19.7 | 7.1% | -2.3% | 5.4% | -17.9% | 57 | BOUNCE FROM SUPPORT | -6.9% | -9.1% | +19.0% | -2.4% |
| GUFICBIO | ₹406.30 | 55.5 | 7.5% | 6.1% | -6.9% | +15.7% | 60 | BREAKDOWN | +70.2% | +1.8% | +16.6% | +3.6% |
| SOLARA | ₹644.40 | – | -0.1% | -1.2% | – | +14.8% | 53 | CONSOLIDATING DOWN | +55.2% | +69.8% | +19.5% | -1.5% |
| INDSWFTLAB | ₹360.90 | 53.9 | 8.5% | -19.7% | -3.2% | +249.6% | 59 | BREAKDOWN | +180.7% | +63.6% | +21.0% | +12.8% |
| RPGLIFE | ₹2,719.20 | 37.6 | 16.3% | 11.3% | 19.4% | +27.6% | 75 | APPROACHING SUPPORT | +17.1% | +3.0% | +15.9% | +10.6% |
| GUJTHEM | ₹363.50 | 81.3 | 28.0% | 3.8% | -7.0% | -9.7% | 58 | BREAKDOWN | +22.0% | +1.8% | +22.0% | -0.9% |
| HIKAL | ₹213.70 | – | -1.9% | -5.4% | – | -9.2% | 52 | CONSOLIDATING DOWN | -67.0% | -151.4% | +7.7% | -22.7% |
Data from TradeAlone · Updated daily
No news tagged for UNICHEMLAB yet.
